Predictors of renal function decline in patients with gastroenteropancreatic neuroendocrine tumors undergoing [177Lu]Lu-DOTA-TATE therapy
Abstract Background Peptide receptor radionuclide therapy (PRRT) with [177Lu]Lu-DOTA-TATE is an established treatment for advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). While overall renal safety is high, the kidneys remain an organ at risk. This study aimed to determine whether c...
Saved in:
| Main Authors: | Felix L. Herr, Christian Dascalescu, Victoria Fusch, Caroline Smith, Ricarda Ebner, Mathias J. Zacherl, Florian Eckenweber, Konrad Klimek, Christoph J. Auernhammer, Christine Spitzweg, Jens Ricke, Maurice M. Heimer, Clemens C. Cyran, Rudolf A. Werner, Gabriel T. Sheikh |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2025-08-01
|
| Series: | EJNMMI Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13550-025-01305-8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Radiation exposure and protection advice after [177Lu]Lu-DOTA-TATE therapy in China
by: Fei Liu, et al.
Published: (2024-11-01) -
Blood-based transcriptomic biomarkers for response to [177Lu]Lu-DOTA-TATE therapy in neuroendocrine tumors
by: Hyunpil Sung, et al.
Published: (2025-08-01) -
Hematological Side Effects of <sup>177</sup>Lu-DOTA-TATE Therapy in Patients with NENs
by: Luciano Carideo, et al.
Published: (2024-12-01) -
Evolution of dosimetric parameters through PRRT and potential impact on clinical practice: data from the prospective phase II LUMEN study
by: Rachele Danieli, et al.
Published: (2024-11-01) -
Somatostatin-receptor avidity of pancreatic neuroendocrine tumor thrombus in porto-caval venous systems on 99mTc-Octreotide and posttherapeutic 177Lu-DOTA-TATE scans
by: Mahasti Amoui, et al.
Published: (2021-07-01)